On June 30, Abivax S.A. rose 21.37% in after-hours trading, trading at approximately $114.73/share, with turnover of $20.74 million. The rebound reflects continued digestion of safety concerns surrounding the company's core drug obefazimod.

The stock had previously plunged nearly 50% from around $130 to approximately $70 after multiple cancer cases emerged in the 50mg arm of its Phase 3 ABTECT maintenance trial. However, some investors now believe the cancer cases are more likely age-related rather than drug-induced, and notably the trial did meet its primary endpoint in both the 25mg and 50mg doses for moderately to severely active ulcerative colitis.

Supporting the recovery, Morgan Stanley maintained an Overweight rating with a $132 price target, while consensus among 14 covering analysts remains unanimously bullish. Additionally, the European healthcare sector has been leading broader markets, with Abivax shares already rebounding significantly on European exchanges. The company also recently completed a $45 million ADS offering and a $90 million royalty certificate repurchase, strengthening its financial position ahead of potential commercialization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)